The immuno-oncology arena is seeing a new player enter the hottest game in R&D. And some of the biggest companies in biopharma are pushing into early-stage studies, spawning a fresh rivalry as researchers jockey for the lead position in what promises to be a hotly contested race.
Last year, U.K. officials lambasted Pfizer's proposed takeover of AstraZeneca, and Pfizer has drawn criticism for its hard line on generic Lyrica use. Now, Britain's competition watchdog is accusing the drugmaker of violating U.K. and European laws by jacking up costs for another epilepsy med.
Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics, not to mention a solid biosimilars pipeline.
So far, the market looks ripe for copies of Teva's multiple sclerosis hit, Copaxone. And Pfizer wants to get in on that.
Pfizer's Ibrance was a drug to watch from the get-go: It won FDA approval months early, and early uptake was quick. But now, its spotlight is getting even brighter.
The world's biggest vaccine by sales--Prevnar 13--just keeps getting bigger. And in doing so, the shot helped Pfizer notch 44% vaccines growth for the second quarter as the unit saw sales grow from $1.09 billion in last year's Q2 to $1.58 billion during the period this year.
Millions of Americans take statins to help control their cholesterol and try to stay heart healthy. You just can't count on them to handle that on their own, Pfizer has found. And so the maker of Lipitor, the most successful statin of them all, has given up on its efforts to move the drug to an over-the-counter treatment.
Analysts expected Pfizer's Established Products division to keep suffering on generic competition to Celebrex and Zyvox in Q2. But they didn't foresee new-launch Ibrance and key vaccine Prevnar 13 picking up as much slack as they did, helping the pharma giant surpass both top- and bottom-line estimates and prompting it to up its guidance.
Pfizer, among the horde of drugmakers looking to Cambridge, MA, for innovation, is expanding its outpost in the city's Kendall Square neighborhood, planning to plant about 1,000 workers in what has become biotech's fastest-growing neighborhood.
Though it can boast its ownership of the world's bestselling vaccine in Prevnar, Pfizer is not stopping there. On Tuesday, the New York City-based pharma unveiled details of its effort to build out its vaccines business by researching a range of conditions from birth until old age.